". . . despite advances in therapy, infection remains a major risk in CLL and is a key challenge in CLL management. People with CLL face varied immune challenges – in addition to infections – along the patient pathway, which form a major part of managing day-to-day life with CLL."
The SARS-CoV-2 pandemic has put additional pressure on those with CLL. On the flip side, during the pandemic, more people have become aware of some of the challenges facing those who are immunocompromised.
"Given the spotlight the COVID-19 pandemic shone on immunocompromised people, the CLL Advocates Network (CLLAN) and AstraZeneca wanted to build on this public recognition to positively impact the care and support offered to people with CLL."
So, they produced a White Paper titled "Compromised: Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia" which was released this week (15 May 2023).
clladvocates.net/wp-content...
The White Paper highlights 4 key recommendations:
"Creating global clinical guidance for monitoring and managing immunosuppression in people with CLL
Ensuring that immunocompromised status is flagged in the patient health records of people with CLL
Instigating education and awareness raising activities amongst healthcare professionals, especially primary care physicians
Making shared decision-making and personalised approaches commonplace in the management and care of people with CLL"
It notes that:
"Further work is required to ensure that national haematological bodies recognise and adopt similar standards of immunocompromised care; the International Workshop on CLL (iwCLL) may be well placed to develop more specific guidelines and work with national champions to ensure effective implementation."
As well as highlighting the role health professionals can play, the report acknowledges that:
"Empowering people with CLL to take an active role in the management of their disease could also be beneficial"
It explains that immune-related challenges can impact the social life and mental health of someone living with CLL and discusses measures to prevent specific infections including pneumococcal, flu, Covid-19 and shingles while acknowledging that "consolidated practice guidelines for infection prophylaxis in CLL should be developed."
It also discusses autoimmune complications (AICs), the risks of severe COVID-19 and the risk of secondary cancers in those with CLL.
"Elevated risks for secondary cancer have also been reported in people with CLL, including non-melanoma skin cancer, melanoma, sarcoma, and lung, renal, and prostate cancers."
"Additional cancer rates are relatively low in people with CLL, but awareness of the possibility can help to monitor and reduce the likelihood that a potential additional cancer becomes challenging to treat. People with CLL have an impaired immune system, and this may partly explain the increased incidence of secondary malignancies."
As well as reading the full report, you may also wish to visit or revisit our pinned post about vaccinations for those with CLL: healthunlocked.com/cllsuppo... and our pinned post about immunity that is maintained by AussieNeil : healthunlocked.com/cllsuppo...
Enormous thanks to the White Paper working group: Nick York (Chair), Pierre Aumont, Rita Christensen, Lea Koren, Jan Rynne and Raymond Vles. The paper was commissioned and funded by AstraZeneca and co-developed and reviewed by CLLAN and AstraZeneca. "CLLAN representatives did not receive any financial compensation in relation to this white paper." "The working group’s thanks also go to Professor Paul Moss, University of Birmingham (UK), and Professor Clemens-Martin Wendtner, München Klinik (Germany), who kindly acted as non-compensated reviewers of this white paper and provided input on content."
clladvocates.net/whitepaper...
Note: this is an open, unlocked post so that it will reach more people.
CLLerinOz